Neurorehabilitation medical equipment company Mobia Medical (MOBI.US) plans to go public on NASDAQ, with plans to raise up to $100 million.

Mobia Medical, a neurorehabilitation medical device company based in Austin, Texas, officially submitted its initial public offering application to the U.S. Securities and Exchange Commission (SEC) on April 17. According to the prospectus, the company plans to list on the Nasdaq Global Market under the stock symbol "MOBI," with a proposed fundraising size of up to $100 million. Bank of America Securities, J.P. Morgan, and Goldman Sachs Group, Inc. will serve as joint lead underwriters for the IPO, and specific pricing terms have not been disclosed. As a commercial-stage medical device company, Mobia Medical's core competitiveness lies in its proprietary developed Vivistim vagus nerve stimulation system. This system is currently the first and only implantable solution approved by the U.S. Food and Drug Administration (FDA) specifically designed to improve upper limb motor function in chronic ischemic stroke survivors. The Vivistim system provides precise electrical stimulation during functional movement training for patients, utilizing the principles of neuroplasticity to help damaged nerves reconnect and significantly enhance hand and arm function in patients. The management estimates that there are over 4 million chronic ischemic stroke survivors worldwide, with 1 million survivors having the necessary health conditions, cognitive abilities, and motivation to participate in post-stroke rehabilitation. Based on pricing of the system, this represents a $30 billion market opportunity. Founded in 2007 in Austin, Texas, the company had revenue of $32 million in the 12 months ending on December 31, 2025, achieving over 100% year-on-year growth compared to $15.6 million in the 2024 fiscal year.